Table 1 Patients’ characteristics at baseline
Summary statistics | ||
|---|---|---|
Age (n = 35) | At the beginning of the study | 53.32 (13.63) (22.23;74) |
Number of patients ≥ 65 years (LORA) | 8/35 (22.86%) | |
Gender (n = 35) | Female | 24/35 (68.57%) |
Disease duration (n = 35) | Duration from initial diagnosis until inclusion in the study (in months) | 0.2 (0.42) (0;1.98) |
Duration of symptoms (in months) | 1.3 (1.25) (0.13;4.5) | |
Disease Activity Score 28 (DAS28) | DAS28(ESR) (n = 34) | 5.55 (1.11) (3.55;7.57) |
DAS28(CRP) (n = 31) | 5.02 (1.12) (3.09;6.77) | |
Laboratory parameters | ESR (1 h/mm) (n = 34) | 39.62 (22.23) (8;95) |
CRP (n < 5.0 mg/l) (n = 32) | 16.34 (17.89) (0;66.52) | |
Clinical examination (n = 35) | Swollen joint count (28-SJC) | 6.31 (4.73) (1;20) |
Tender joint count (28-TJC) | 10.26 (7.85) (1;25) | |
VAS (0–100 mm) for disease activity | Patient (n = 35) | 58.14 (18.79) (20;100) |
Physician (n = 21) | 54.52 (16.58) (30;90) | |
Rheumatoid factor (RF) | Seropositive (n = 34) | 15/35 (42.86%) |
Rheumatoid factor IgA (n = 29) | 93.23 (166.03) (0.1;500) | |
Rheumatoid factor IgM (n = 31) | 59.64 (113.93) (0.1;500) | |
Anti-citrullinated peptide antibodies (ACPA) (n = 35) | Level | 250.34 (393.27) (0.42;1000) |
Positive | 4/35 (11.43%) | |
Highly positive | 15/35 (42.86%) |